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INTRODUCTION
Non-steroidal anti-infl ammatory drugs (NSAIDs) are widely used as analgesics ( 1, 2 ) . Ibuprofen is the most commonly used nonaspirin NSAID, with about one quarter of the US population aged 17 years or older reporting ibuprofen intake in the past month ( 2 ) . Th e main factor that limits NSAID use is the deve lopment of upper gastrointestinal (GI) adverse eff ects including ulcers, complications such as bleeding, and dyspepsia. Strategies recommended ( 3 -6 ) to decrease GI injury in NSAID users include co-therapy with misoprostol or proton-pump inhibitors and / or use of COX-2 selective inhibitors.
Histamine 2 -receptor antagonists (H2RAs) have not been recommended for preventive therapy in NSAID users because, when given in standard doses, they signifi cantly decrease duodenal but not gastric ulcers ( 3, 7 ) . However, a Cochrane systematic review of placebo-controlled randomized trials ≥ 3 months ( 7 ) identifi ed one study showing a signifi cant benefi t of double-dose H2RAs in reducing both gastric ulcers (relative risk (RR) = 0.42, 95 % confi dence interval, 0.18 -0.97) and duodenal ulcers (RR = 0.19, 0.04 -0.85) (8) . Th e RRs for proton-pump inhibitor vs. placebo co-therapy in the meta-analysis were 0.40 (0.32 -0.51) for gastric ulcers and 0.19 (0.09 -0.37) for duodenal ulcers ( 7 ) .
Double-Blind Randomized Trials of Single-Tablet Ibuprofen / High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers
Although many national and international groups recommend protective therapy in NSAID users at increased risk of GI events ( 3 -6 ) , most such patients are not prescribed protective therapy ( 8, 9 ) . In addition, patients may not take their protective cotherapy along with their NSAID, especially if they are not experiencing any symptoms, and decreased adherence is associated with a signifi cantly increased risk of developing upper GI ulcers or bleeding ( 10 -13 ) . For example, van Soest et al. ( 13 ) reported that the risk of an upper GI clinical event (bleeding, perforation, or symptomatic ulcer) in NSAID users at increased GI risk rose 16 % for every 10 % decrease in the proportion of time a proton-pump inhibitor or H2RA was prescribed. Mechanisms that ensure adherence to protective therapy, such as the combination of an NSAID and a protective agent in one pill, theoretically should decrease the GI risk associated with the NSAID therapy.
We performed the REDUCE trials (Registration Endoscopic Studies to Determine Ulcer Formation of HZT-501 Compared with Ibuprofen: Effi cacy and Safety Studies) to assess whether double-dose famotidine given in a single-tablet combination with ibuprofen (HZT-501 (ibuprofen 800 mg plus famotidine 26.6 mg); Horizon Pharma, Northbrook, IL) signifi cantly reduces the proportion of patients who develop gastric ulcers (REDUCE-1) or upper GI (gastric or duodenal) ulcers (REDUCE-2) during 24 weeks of treatment as compared with ibuprofen in adult NSAID users.
METHODS

Patients
Male and female patients aged 40 -80 years expected to require daily NSAID therapy for at least 6 months for pain and / or infl ammatory conditions were eligible. Exclusion criteria included history of erosive esophagitis; history of GI complications (bleeding, perforated ulcer, gastric outlet obstruction due to an ulcer); history of NSAID-associated asthma exacerbations, acute renal failure, interstitial nephritis, or hepatitis; history of GI malignancy; history of myocardial infarction, unstable cardiac arrhythmias, or stroke within 6 months of study entry; coronary artery bypass graft surgery within 14 days of study entry; uncontrolled congestive heart failure or hypertension at entry; acid-suppressive therapy or misoprostol within 14 days before study entry or investigational drug or NSAIDs (including aspirin > 325 mg daily) within 30 days before study entry; ulcer or > 5 erosions on screening upper GI tract endoscopy; or one of the following abnormalities on baseline laboratory testing: creatinine clearance < 45 ml / min; aminotransferase > 2.5 times upper limit of normal; fasting blood sugar > 200 mg / dl; serum pregnancy test positive; serologic tests positive for human immunodefi ciency virus, hepatitis B, or hepatitis C; or stool antigen for H. pylori positive.
Study design
Patients were randomly assigned, using a computer-generated randomization schedule, from a central location utilizing an interactive voice response system with blinded medication kit number allocation in a 2:1 ratio to identical-appearing tablets of HZT-501 (800 mg ibuprofen and 26.6 mg famotidine) or ibuprofen (800 mg) thrice daily for 24 weeks. Patients, care providers, and all study personnel were blinded to the treatment. Patients were stratifi ed for two risk factors for ulcer development: concomitant use of low-dose aspirin ( ≤ 325 mg daily) and / or anticoagulant medication and history of gastric or duodenal ulcer. In addition to the screening upper endoscopy at baseline, patients had endoscopy at weeks 8, 16, and 24 (or earlier if premature study termination) of study therapy. Th e following medications were proscribed during the study: medications that may reduce ulcers (e.g., misoprostol, proton-pump inhibitors, and non-study H2RAs), non-study NSAIDs other than low-dose aspirin taken for cardiovascular prophylaxis. In addition, antacids could not be taken for > 3 days in any 2-week period; patients requiring further antacid therapy were to be discontinued from the trial. Th e study medication was dispensed in an 8-week supply at 0, 8, and 16 weeks. Compliance was determined by pill count of returned bottles of study medication. Serum chemistries, complete blood count, and prothrombin time were performed at screening, week 8, week 16, and the fi nal study visit (week 24 or earlier if early termination). Urinalysis was done at baseline and fi nal visit.
End points and analysis
Th e primary end point for REDUCE-1 was gastric ulcers identifi ed at endoscopy during the 24-week study period, with three secondary end points: upper GI ulcers (gastric and duodenal), duodenal ulcers, and GI complications (bleeding, ulcer perforation, and gastric outlet obstruction due to ulcer). Th e primary end point for REDUCE-2 was upper GI (gastric or duodenal) ulcers identifi ed at endoscopy during the 24-week study period, with three secondary end points: gastric ulcers, duodenal ulcers, and GI complications. An endoscopic diagnosis of ulcer required unequivocal depth and diameter of ≥ 3 mm. Th e predefi ned primary population for analysis included all patients who were randomized, received a dose of study medication, and had at least one study-mandated follow-up endoscopy.
A sample size for REDUCE-1 of 875 was calculated based on a 90 % power to detect a diff erence of 6 % vs. 14 % in the incidence of gastric ulcers with a two-sided α of 0.05 and assuming a 15 % dropout rate. A sample size for REDUCE-2 of 600 was calculated based on a 90 % power to detect a diff erence of 6 % vs. 16 % in the incidence of upper GI ulcers with a two-sided α of 0.05 and assuming a 15 % drop-out rate. Statistical comparisons were predefi ned to be done with a fi xed testing sequence (hierarchical) in the following order of primary followed by secondary end points: REDUCE-1: gastric ulcers, upper GI ulcers, duodenal ulcers, GI complications; REDUCE-2: upper GI ulcers, gastric ulcers, duodenal ulcers, GI complications. With this approach, the fi rst null hypothesis that is accepted (i.e., P ≥ 0.05) will cause immediate acceptance of all subsequent null hypotheses in the sequence (subsequent comparisons will be considered not signifi cantly diff erent and no statistical comparison will be performed). Th is approach also requires no α adjustment for multiple comparisons ( 14 ) .
STOMACH
High-Dose Famotidine for Reduction of NSAID Ulcers
Th e two diff erent primary end points in the individual studies were chosen to address both the more clinically relevant end point of upper GI ulcers (gastric and / or duodenal) and the traditional US FDA (Food and Drug Administration) end point of gastric ulcers. In clinical practice, physicians and patients are concerned about preventing ulcers, whether they are gastric or duodenal, and many clinical trials use this primary end point. However, the FDA generally has approved antisecretory medications for prevention of gastric ulcers (e.g., lansoprazole and esomeprazole). Th ese two trials were designed to be used for registration, and, in pretrial meetings, the FDA agreed to the use of the diff erent end points in the two trials.
Comparison between treatment arms of the crude proportions of patients with ulcers at 24 weeks with a Cochran -Mantel -Haenszel test stratifi ed by the two randomization risk factor strata (use of low-dose aspirin and other anticoagulants, prior ulcer history) was specifi ed as the primary statistical analysis at the time of sample size calculation and study initiation. Before study termination and unblinding, the primary analysis was changed to a comparison between treatment arms of the life table estimates of the proportion of patients with ulcers at 24 weeks employing a modifi ed χ 2 using the sum of squares from the life table in the error term, with the comparison of crude proportions using the Cochran -Mantel -Haenszel test maintained as a secondary analysis. Numbers-needed-to-treat (NNTs) and absolute risk reductions were calculated using crude proportions.
A pooled analysis of the patients in REDUCE-1 and -2 was prespecifi ed, with the primary end point being upper GI ulcers, and the secondary end points being gastric ulcers and duodenal ulcers. Th e proportion of patients developing ulcers was also prespecifi ed to be assessed in the following subgroups: use of lowdose aspirin and / or anticoagulants, prior ulcer history, age ( ≥ 65 vs. < 65 years), gender, and race. In addition, post hoc subgroup analysis included use of low-dose aspirin alone, and presence or absence of erosions at screening endoscopy. For comparison of Th e trials continued until their planned completion based on the prespecifi ed sample sizes. Selected baseline characteristics of the primary population analyzed in the two study groups for each trial are shown in Table 1 . Reason for NSAID use across both trials included pain (37.9 % ), osteoarthritis (50.6 % ), rheumatoid arthritis (3.5 % ), and other (7.8 % ). Th e initial results aft er data lock and unblinding in REDUCE-1 for the primary end point of proportion of patients with gastric ulcers at 24 weeks was 12.9 % for HZT-501 and 25.3 % for ibuprofen ( P = 0.0009; NNT = 11). Th e initial results for the primary end point in REDUCE-2 showed the proportions of patients with upper GI ulcers of 13.8 % for HZT-501 and 22.6 % for ibuprofen ( P = 0.0304; NNT = 11).
Aft er unblinding and performance of the statistical analyses, a review of endoscopy reports revealed that some patients with esophageal ulcers had been incorrectly assigned as having gastric subgroups with < 100 patients across the combined treatment arms, a Fisher ' s exact test was used. Th e independent variables prior ulcer history, gender, age, low-dose aspirin use, baseline erosions, and therapy also were included in a proportional hazards model to determine the eff ect on the dependent variable of development of upper GI ulcer. Treatment-by-subgroup interaction was also assessed among these subgroups in the model. A post hoc fi xed eff ect meta-analysis of the results of the two studies for end points of upper GI, gastric, and duo denal ulcers was also performed (Review Manager 5.1, Cochrane Collaboration, Copenhagen, Denmark).
Statistical comparison between the study groups in the population of all patients randomized was also prespecifi ed for common adverse events (occurring in > 5 % of patients) with a CochranMantel -Haenszel test. In addition, we prespecifi ed comparison of the proportion of patients who reported any symptom consistent with dyspepsia (e.g., dyspepsia, upper abdominal pain or discomfort, epigastric pain or discomfort, stomach pain or discomfort; with and without nausea).
All study patients provided written informed consent and the study was approved by institutional review boards for all participating centers.
STOMACH
High-Dose Famotidine for Reduction of NSAID Ulcers
Results of the pooled analysis of the two studies are also shown in Table 2 . When a fi xed eff ect meta-analysis of the two studies was performed, the diff erences and 95 % confi dence intervals were identical to those shown in Table 2 for the pooled analyses of upper GI, gastric, and duodenal ulcers without evidence of heterogeneity ( I 2 = 0 for upper GI, gastric, and duodenal ulcer analyses). In addition, when the Cochran -Mantel -Haenszel analysis was re-run with study (REDUCE-1 or -2) included in the model, the P values for comparisons of all three end points remained < 0.0001.
Th e combined trial data of the primary population was used in a proportional hazards analysis to examine multiple risk factors in relation to development of upper GI ulcers. Treatment with HZT-501 (vs. ibuprofen) was associated with a signifi cantly lower risk ratio ( Th e eff ect of treatment was also examined within subgroups for the combined studies. Th e forest plot of these is shown in Figure 3 . ulcers. An adjudication committee of two independent gastroenterologists then reviewed all positive endoscopy reports to determine how many ulcers had been misclassifi ed. In the primary population, fi ve patients in REDUCE-1 (one HZT-501 (no ulcer), four ibuprofen (four esophageal ulcers)) and seven patients in REDUCE-2 (three HZT-501 (two no ulcer, one esophageal ulcer), four ibuprofen (one no ulcer, three esophageal ulcers)) had esophageal ulcers misclassifi ed as gastric ulcers or had no gastric ulcer present; duodenal ulcers were not aff ected. Th e results for the analyses were then re-run with these patients no longer listed as having gastric ulcers. Th ese postadjudication results are presented in Table 2 . In REDUCE-1, the primary end point of proportion of patients with gastric ulcers at 24 weeks was 12.7 % for HZT-501 and 22.9 % for ibuprofen ( P = 0.0044; NNT = 12). Th e results for the primary end point in REDUCE-2 showed the proportions of patients with upper GI ulcers of 13.0 % for HZT-501 and 20.5 % for ibuprofen ( P = 0.0587).
Assessment of the secondary ulcer end points in REDUCE-1 revealed that signifi cantly fewer patients receiving HZT-501 developed upper GI ulcers in both the initial (NNT = 9) and postadjudication analysis (NNT = 10), and signifi cantly fewer patients developed duodenal ulcers (NNT = 25). Assessment of secondary end points in REDUCE-2 showed that the 6.7 % reduction in life table estimate of gastric ulcers was not signifi cant in the initial comparison ( P = 0.0795) and the 5.3 % reduction in the post-adjudication analysis was not formally tested based on the predefi ned hierarchical testing sequence for the analysis. Th e combined trial cumulative incidence for crude rate of ulcers by visit is shown in Figure 2 . 
Gastric ulcers
Life 
Duodenal ulcers
Life table % 2.1 % * 7.1 % 0.9 % 6.6 % 1.6 % * 6.9 % Crude rate % ( n ) 1.3 % (7) No signifi cant treatment-by-subgroup interactions were identifi ed for the subgroups assessed (all P values > 0.10).
Only two adverse event terms were reported in either study at a rate of ≥ 5 % : dyspepsia and nausea. Th e rates for HZT-501 vs. ibuprofen in the pooled results were 4.7 % vs. 8.0 % for dyspepsia and 5.8 % vs. 4.7 % for nausea. However, the proportion of patients with one or more predefi ned symptoms consistent with dyspepsia was not signifi cantly diff erent between HZT-501 and ibuprofen (12.3 % vs. 14.9 % ). GI complications were reported by investigators for three patients (0.6 % ) given HZT-501 and zero given ibuprofen in REDUCE-1. Th ese were GI bleeding episodes in which hemoglobin dropped 1.6, 2.1, and 3.1 g / dl without clinical evidence of overt GI bleeding, transfusions, or hospitalizations. Gastric erosions were noted at endoscopy in all three patients. No GI complications were reported in REDUCE-2. One death occurred in the two studies: a 48-year-old female in the ibuprofen group died of cardiorespiratory arrest and multiorgan system failure attributed to acetaminophen toxicity. 
DISCUSSION
Th e goal of the REDUCE trials was to confi rm the results of a single smaller study by Taha et al. ( 15 ) , and demonstrate a signifi cant decrease in NSAID-associated gastric and duodenal ulcers with double-dose famotidine, using a combination tablet of ibuprofen and famotidine.
Two studies of identical design were performed, as is gene rally required when phase 3 trials are used to apply for regulatory approval. Th e trials diff ered only in their sample size and their primary vs. secondary end point (gastric ulcers followed by upper GI ulcers in REDUCE-1 and upper GI ulcers followed by gastric ulcers in REDUCE-2). Aft er unblinding and initial analyses were performed, it was discovered on adjudication of endoscopy reports that 12 patients listed as having gastric ulcers actually had esophageal ulcers or no ulcers. Th erefore, analyses were re-run using the post-adjudication data, with these 12 patients no longer listed as having gastric ulcers.
Th e larger REDUCE-1 trial demonstrated a signifi cant decrease in the primary end point of gastric ulcers ( P = 0.0044) as well as in duodenal ulcers. Th e smaller REDUCE-2 trial did not show a signifi cant diff erence in the post-adjudication primary analysis of life table estimates of upper GI ulcers, with a P value of 0.0587; the secondary statistical comparison of crude proportions of upper GI ulcers revealed a P value of 0.0070. Pooled analysis of the trials showed a signifi cant decrease in upper GI ulcers with an NNT of 11, as well as signifi cant decreases in both components, gastric ulcers and duodenal ulcers.
Multivariable analysis revealed a signifi cant RR reduction in ulcers of ~ 55 % with HZT-501 aft er adjustment for risk factors that may infl uence the development of ulcers, such as age, ulcer history, aspirin use, and baseline erosions. Furthermore, the treatment eff ect of HZT-501 was not signifi cantly diff erent in subgroups of patients with or without these characteristics. Of interest, there was no decrement in treatment eff ect noted among patients taking low-dose aspirin. Ibuprofen was chosen as the NSAID studied because it is the most widely used non-aspirin NSAID in the United States ( 2 ). Although famotidine is generally given twice daily, ibuprofen at full doses for arthritis is typically given thrice daily. Th e double-dose famotidine was therefore given as three daily doses of 26.6 mg in the combination tablet. A preliminary study suggested that 26.6 mg thrice daily produces gastric acid suppression similar to 40 mg twice daily aft er 1 day ( 16 ) . Also, oral administration of HZT-501 is bioequivalent to concurrent oral administration of equivalent separate doses of ibuprofen and famotidine ( 17 ) .
Previous trials have suggested that H2RAs may decrease upper GI symptoms in patients taking NSAIDs ( 18, 19 ) . We did not fi nd a signifi cant decrease in the proportion of patients spontaneously reporting a composite of symptoms consistent with dyspepsia. Future studies should formally assess NSAID users with a patient-reported outcome instrument validated for NSAID-associated dyspepsia.
Upper GI complications such as bleeding are more important clinically than ulcers identifi ed at a scheduled endoscopy, although results of endoscopic ulcer trials in NSAID users generally correlate with results in outcome trials assessing upper GI complications ( 7, 20 ) . Nevertheless, our study was insuffi cient in size and duration to reasonably assess complications, and the results do not demonstrate a benefi t in complications. No patients had overt bleeding, obstruction, or perforation. Two patients in the HZT-501 arms (and none in the ibuprofen arms) had asymptomatic hemoglobin decreases > 2.0 g / dl, the level typically used in outcome trials as a clinically relevant hemoglobin drop ( 21, 22 ) , and a third had a 1.6 g / dl decrease. Chan et al. ( 22 ) recently showed that such hemoglobin drops are much more common than overt complications in patients taking an NSAID plus antisecretory therapy, and that a majority are probably of small intestinal origin. Our patients with hemoglobin drops had gastric erosions noted, although no examination was performed to assess potential small intestinal injury.
Very few patients were on antiplatelet agents other than low-dose aspirin so our study is unable to assess any potential interactions of famotidine with clopidogrel. Famotidine, like ranitidine and unlike cimetidine, shows little or no interaction with the hepatic cytochrome P450 system ( 23 ) .
In summary, the combined results of two studies indicate that double-dose famotidine plus ibuprofen, given as a combination tablet, decreases endoscopic upper GI ulcers as compared with ibuprofen alone. Use of a combination tablet theoretically should improve adherence to antisecretory therapy as compared with use of separate individual NSAID and antisecretory agents, but future studies will be necessary to prospectively study adherence and the eff ect on endoscopic or clinical outcomes.
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